BeiGene
BGNE
#881
Rank
S$28.88 B
Marketcap
$263.10
Share price
1.71%
Change (1 day)
-0.19%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -S$1.19 B

According to BeiGene 's latest financial reports the company's current earnings (TTM) are -S$1.16 B. In 2023 the company made an earning of -S$1.58 B an increase over its 2022 earnings that were of -S$2.34 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -S$1.19 B-24.49%
2023 -S$1.58 B-32.52%
2022 -S$2.34 B24.39%
2021 -S$1.88 B-13.21%
2020 -S$2.16 B72.69%
2019 -S$1.26 B36.01%
2018 -S$0.92 B616.83%
2017 -S$0.13 B-15.24%
2016 -S$0.16 B107.91%
2015 -S$72.78 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-S$23.65 M-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$0.32 B-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA